Abstract:5688 CRM1 is an essential protein required to export a set of ‘cargo’ proteins which bear a leucine-rich nuclear export sequence (NES) from the nucleus to the cytoplasm. Examples of cancer-related proteins bearing CRM1-dependent NESs include p53, BCR-Abl, and FOXO-3a. Nuclear sequestration of these CRM1 ‘cargo’ proteins upon inhibition of CRM1 can lead to cell growth inhibition in normal cells or apoptosis in cancer cells. The identification of CRM1 as a novel target in cancer came from the study of Leptomycin B (LMB) and its analogs. These molecules are potent cytotoxic agents which belong to a group of polyketide natural products known as nuclear export inhibitors (NEIs). LMB and its analogs covalently bind to the nuclear exportin CRM1 and thereby inhibit its ability to shuttle cargo proteins to the cytoplasm. The development of LMB was limited by the significant toxicity observed in previous studies (Newlands, et al., 1996, Br. J. Can., 74: 648-649). We have recently developed a series of NEI analogs with significantly improved biological and pharmacological properties over LMB. Upon examination of the activity of these molecules in leukemia cell lines, we found that NEIs were very potent in vitro in ALL (Molt-4, CCRF-CEM, Jurkat) and AML (MV-4-11) cell lines. Exposure to NEIs led to a rapid and dramatic induction of multiple markers of apoptosis (caspases, Annexin V binding). Based on these results, we examined the activity of two NEI analogs, KOS-1815 and KOS-2464, in murine leukemia xenograft models. Both of these drugs, when dosed on a weekly schedule, significantly inhibited the growth of MV-4-11 (T/C = ~22% for KOS-2464 and ~26% for KOS-1815) and Molt-4 (T/C = ~38% for KOS-2464 and ~29% for KOS-1815) xenografts. In addition, a single administration of KOS-2464 or KOS-1815 induced regression of large (>1000 mm3) CCRF-CEM xenografts. KOS-2464 was very well-tolerated at efficacious doses in all of these leukemia models, while KOS-1815 induced a ~5 to 10% transient body weight loss upon dosing. Finally, we established a Molt-4 orthotopic leukemia model in mice. Weekly dosing of KOS-1815 and KOS-2464 for three weeks, beginning eight days after cancer cell implantation, doubled survival of these leukemic mice. Median survival increased from 25 days for the control group to 50+ days for the drug-treated groups (56 days for KOS-2464 and 50 days for KOS-1815). Studies are ongoing to gain further insight into the mechanism by which these molecules exert their activity in leukemia models. Taken together, the current study shows that KOS-2464, our lead NEI analog, with its novel mechanism of action and wide therapeutic window, has significant potential as a novel anti-cancer agent, especially for the treatment of leukemia.

Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors

Discovery of Potent Covalent CRM1 Inhibitors Via a Customized Structure-Based Virtual Screening Pipeline and Bioassays

Discovery of a Hidden Pocket beneath the NES Groove by Novel Noncovalent CRM1 Inhibitors

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Discovery of SZJK-0421: A Novel Potent, Low Toxicity, Selective Second Generation of CRM1 Inhibitor for the Treatment of Both Hematological and Solid Tumors

Anti-tumor Activity of Novel Nuclear Export Inhibitors (neis) in Multiple Murine Leukemia Models

Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma

Design, synthesis and biological evaluation of acyl hydrazones-based derivatives as RXRα-targeted anti-mitotic agents

Computer-aided molecular design and optimization of potent inhibitors disrupting APC‒Asef interaction

Discovery of a Novel Aminocyclopropenone Compound That Inhibits BRD4-Driven Nucleoporin NUP210 Expression and Attenuates Colorectal Cancer Growth

Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents

Discovery of Phenylpyrazole Derivatives As a New Class of Selective Inhibitors of MCL-1 with Antitumor Activity

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer

Design, synthesis, molecular modeling and evaluation of 2,4-diaminopyrimidine analogues as promising colorectal cancer drugs

Discovery of potential novel CRBN modulators by virtual screening and bioassay

Synthesis and biological evaluation of a novel c-Myc inhibitor against colorectal cancer via blocking c-Myc/Max heterodimerization and disturbing its DNA binding

Discovery of bipyridine amide derivatives targeting p RXRα-PLK1 interaction for anticancer therapy

2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents

Abstract 4: Discovery of Novel and Highly Potent Small Molecule Inhibitors of Chemokine Receptor CXCR4

Discovery of New Lenalidomide Derivatives As Potent and Selective GSPT1 Degraders.